More on ALNY
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $242.61 |
|
|||
| Open | $241.90 | ||||
| 52 Wk High | $109.10 | ||||
| 52 Wk Low | $31.38 | ||||
| Day High | $253.25 | ||||
| Day Low | $240.00 | ||||
| P/E | N/A | ||||
| EPS | $-1.45 | ||||
| Volume | 836,054 | ||||
- Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
- Biotech sector Q1 earnings preview from RBC Capital Markets
- Piper Sandler: 'What Biotech Names to Own in Market Volatility'
- Bernstein Recommends Three US Biotech Stocks Amid 'Heightened Regulatory Uncertainty'
- Form SCHEDULE 13G/A ALNYLAM PHARMACEUTICALS, Filed by: VANGUARD GROUP INC
- Form DEFA14A ALNYLAM PHARMACEUTICALS,
- Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
- Stifel Raises Price Target on Alnylam Pharmaceuticals (ALNY) to $345
Entities mentioned with ALNY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- PDUFA | View Related Stories »
- Needham & Company | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
